II. Causes: Negative
- Normal titer less than 1:20 dilution
- See interpretation below regarding titers
III. Causes: Positive
- Normal patient without underlying abnormality: 3-30%
- More common in older women
- Rheumatologic Conditions
- Infection
- Tuberculosis
- Chronic active hepatitis (e.g. Hepatitis C)
- Subacute Bacterial Endocarditis
- HIV Infection
- Miscellaneous Conditions
- Type I Diabetes Mellitus
- Hashimoto Thyroiditis
- Multiple Sclerosis
- Pulmonary fibrosis
- Silicone gel implants
- Pregnant women
- Elderly patients
- Medications (Drug induced Lupus Erythematosus)
IV. Mechanism
- IgG or IgM Antinuclear Antibody (ANA)
- Antibody binds to nuclei or nuclear components
V. Precautions
- Almost all patients with Systemic Lupus Erythematosus (SLE) have a positive ANA titer
- Most patients with a positive ANA titer do not have Systemic Lupus Erythematosus (SLE)
- High False Positive Rate (esp. low titers) and in Autoimmune Conditions (see above)
- ANA Levels fluctuate and do not correlate with response to therapy or with disease activity
- Once ANA test is positive, repeat testing is rarely indicated
VI. Labs: Indirect Immunofluorescence Assay (IIF) Slide test
- Uses fixed and permeabilized human epithelial cells (HEp-2 cells)
- Labor intensive
- Most accurate ANA Test
- Test Sensitivity: 93%
- Test Specificity: 57%
- Positive Likelihood Ratio (LR+) for SLE: 2.2
- Negative Likelihood Ratio (LR-) for SLE: 0.1
- Measures direct binding
- Patient's serum antibodies to cell nuclei
- Specific components of cell nucleus are also bound
- See ANA subunits below
VII. Labs: Enzyme-Linked Immunosorbent Assay (ELISA)
- Less labor intensive and less costly than Indirect Immunofluorescence Assay (IIF) Slide Test
- Less accurate than Indirect Immunofluorescence Assay (IIF) Slide Test
- Test Sensitivity: 81.9%
- Test Specificity: 79.6%
- Positive Likelihood Ratio (LR+) for SLE: 2.97
- Negative Likelihood Ratio (LR-) for SLE: 0.25
VIII. Interpretation: Titer (Dilution)
- Pretest probability affects interpretation
- Primary Care Setting: 2% SLE probability
- Rheumatology Setting: 30% SLE probability
- Low Positive (1:160 or lower): Low significance
- SLE Likelihood: <2% (<26% for rheumatologists)
- High Positive (1:320 or higher): Higher significance
- SLE Likelihood: 2-17% (32-81% for rheumatologists)
- References
IX. Interpretation: ANA Staining Patterns
- Systemic Lupus Erythematosus specific patterns
- Sjogren Syndrome
- Scleroderma Specific Patterns
- CREST Syndrome Specific Patterns
X. Interpretation: ANA Subunits
-
Systemic Lupus Erythematosus
-
Anti-dsDNA (SLE Test Sensitivity: 60%)
- Specific for lupus erythematosus
- Associated with Lupus Nephritis
- Associated with Lupus CNS Involvement
-
Anti-Smith or Anti-Sm (SLE Test Sensitivity: 20-30%)
- Highly specific for lupus erythematosus
-
Anti-ribosomal P (SLE Test Sensitivity: 20-30%)
- Highly specific for lupus erythematosus
- Associated with Lupus Psychosis
-
Anti-RNP (SLE Test Sensitivity: 30-40%)
- Associated with lupus disease activity
- Seen in all cases Mixed Connective Tissue Disease
- Anticardiolipin Antibody
- Lupus Anticoagulant
- Consider Sjogren Antibodies (Anti-SSA and Anti-SSB)
-
Anti-dsDNA (SLE Test Sensitivity: 60%)
- CREST and Scleroderma
- Anti-centromere
- Sensitivity for Scleroderma: 22-36%
- Scl-70 kD kinetochore (Anti-Topoisomerase I)
- Sensitivity for Scleroderma: 22-40%
- Anti-centromere
-
Polymyositis and Dermatomyositis
- Anti-Jo1 (sensitivity: 30%)
- Also in Raynaud's Phenomenon, pulmonary fibrosis
- Anti-Ku
- Anti-Mi2
- Anti-Jo1 (sensitivity: 30%)
- Sjogren Syndrome
- Drug Induced Lupus
- Non-specific
- Anti-ssDNA
- Non-specific and rarely indicated
- Anti-ssDNA
XI. References
- Gladman in Klippel (1997) Rheumatic Diseases p. 255-6
- Peng in Ruddy (2001) Kelley's Rheumatology, p. 161-72
- Ali (2018) Am Fam Physician 98(3): 164-70 [PubMed]
- Callegari (1995) Postgrad Med, 97(4):65-74 [PubMed]
- Lane (2002) Am Fam Physician 65(6):1073-80 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | An autoimmune antibody that is directed against structures within the nucleus of the cell. |
Definition (MSH) | Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. |
Definition (CSP) | autoimmune, pathological antibodies against histones, DNA, nuclear RNA, or other components of the cell nucleus. |
Concepts | Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) |
MSH | D000974 |
SnomedCT | 165849001, 45530001 |
English | Antibodies, Antinuclear, Antibody, Antinuclear, Antinuclear Antibodies, Antinuclear Antibody, Antinuclear Factor, Antinuclear Factors, Factor, Antinuclear, Factors, Antinuclear, antinuclear autoantibody, ANTINUCLEAR FACTOR, antinuclear antibody, antiDNA autoantibody, antinuclear factor, Antinuclear Autoantibody, Antibodies, Antinuclear [Chemical/Ingredient], antinuclear antibody (ANA), anti-nuclear antibody, antinuclear factors, antinuclear antibodies, antinuclear antibody ana, ana, Anti-nuclear factor, Anti nuclear factor, Antinuclear factors, ANF, ANA, ANA - Anti-nuclear antibody, ANF - Anti-nuclear factor, Anti-nuclear antibody, Antinuclear antibody, Antinuclear factor, Antinuclear antibody (substance) |
Swedish | Antinukleära antikroppar |
Finnish | Tumavasta-aineet |
Italian | Fattore antinucleare, Anticorpo antinucleare, Fattori antinucleari, Anticorpi antinucleari |
Russian | ANTINUKLEARNYE FAKTORY, ANTI-DNK ANTITELA, ANTITELA ANTI-DNK, ANTITELA ANTINUKLEARNYE, FLIUORESTSENTNYE ANTINUKLEARNYE ANTITELA, ANTINUKLEARNYE ANTITELA, АНТИ-ДНК АНТИТЕЛА, АНТИНУКЛЕАРНЫЕ АНТИТЕЛА, АНТИНУКЛЕАРНЫЕ ФАКТОРЫ, АНТИТЕЛА АНТИ-ДНК, АНТИТЕЛА АНТИНУКЛЕАРНЫЕ, ФЛЮОРЕСЦЕНТНЫЕ АНТИНУКЛЕАРНЫЕ АНТИТЕЛА |
French | ANTICORPS ANTINUCLEAIRES, Facteurs lupiques, Anticorps anti-nucléaires, Anticorps antinucléaires, Facteurs antinucléaires, Facteurs anti-nucléaires, Anticorps antinucléaire, Anticorps anti-nucléaire, ACAN, FAN (Facteur AntiNucléaire) |
Portuguese | FACTOR ANTINUCLEAR, Anticorpos Antinucleares, Fatores Antinucleares |
Japanese | 抗体-抗核, 抗DNA抗体, 抗核因子, 蛍光抗核抗体, 抗核抗体 |
Croatian | ANTITIJELA, ANTINUKLEARNA |
Polish | Przeciwciała przeciwjądrowe, Czynniki przeciwjądrowe |
Czech | antinukleární protilátky, antinukleární faktory, protilátky antinukleární, antinukleární faktor |
Spanish | FAN, anticuerpo antinuclear (sustancia), anticuerpo antinuclear, factor antinuclear, Anticuerpos Antinucleares, Factores Antinucleares |
German | Antikörper, antinukleäre, Antinukleäre Antikörper, Antinukleäre Faktoren |
Ontology: Anti-nuclear antibody measurement (C0587178)
Definition (NCI_CDISC) | A measurement of the antinuclear antibodies (antibodies that attack the body's own tissue) in a biological specimen. |
Definition (NCI) | The determination of the amount of antinuclear antibodies present in a sample. |
Concepts | Laboratory Procedure (T059) |
SnomedCT | 359788000, 390280009, 79404001, 269837009, 389548001 |
CPT | 86038, 1014272 |
English | ANA, Antinuclear antibodies (ANA), Antinuclear antibody, Antinuclear factor, ANA measurement (procedure), Antinuclear antibody (ANA) measurement, Nuclear antibody, Antinuclear Antibody Measurement, Test;anti nuclear antibodies, antinuclear antibody (ANA) test, anti nuclear antibodies test, anti antibody nuclear test, ANTINUCLEAR ANTIBODIES ANA, Antinuclear antibody measurement (procedure), Antinuclear antibody measurement, Antinuclear antibody (ANA) measurement (procedure), Measurement of antinuclear antibodies (ANA), Anti-nuclear factor level, Anti-nuclear antibody measurement (procedure), Anti-nuclear factor level (procedure), Antinuclear Antibodies, ANA - Anti-nuclear antibody level, Anti-nuclear antibody level, ANA measurement, Anti-nuclear antibody measurement, Anti-nuclear antibody measurement, NOS, ANA measurement, NOS, ANTINUCLEAR ANTIBODIES, Antinuclear antibodies, Anti-nuclear antibody measurement (procedure) [Ambiguous] |
Italian | Anticorpo antinucleo, Anticorpi antinucleo, Anticorpo nucleare, Fattore antinucleare |
Spanish | dosaje de anticuerpos antinucleares, dosaje de AAN, ANA, Factor antinuclear, medición de anticuerpos antinucleares, dosaje de anticuerpos antinucleares (procedimiento), medición de anticuerpos antinucleares (procedimiento), medición de AAN, medición de ANA, medición de anticuerpos anti - ácido desoxirribonucleico, medición de anticuerpos antinucleares (concepto no activo), Anticuerpos antinucleares |
Dutch | antinucleaire factor, ANA, nucleaire antistof, antinucleaire antistof |
French | Anticorps anti-nucléaire, Facteur antinucléaire, ANA, Anticorps anti-nucléaires |
German | nukleaerer Antikoerper, ANA, antinukleaerer Faktor, antinukleaerer Antikoerper |
Portuguese | ANA, Factor antinuclear, Anticorpo nuclear, Anticorpos antinucleares |
Japanese | 抗核抗体, 抗核因子, ANA, 核抗体, コウカクコウタイ, カクコウタイ, コウカクインシ, ANA |
Czech | Antinukleární protilátky, Nukleární protilátky, ANA, Antinukleární faktor |
Hungarian | Antinukleáris antitest, ANA, Antinukleáris faktor, Nukleáris antitest |